AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05727774 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Biking in hot water condition
Description: Training protocol includes 10 water biking sessions in hot water temperature (35°C) for this group
Study NCT05727774 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Water Biking in neutral water condition
Description: Training protocol includes 10 water biking sessions in neutral water temperature (25°C) for this group
Study NCT06395246 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Continuous calorie restriction
Description: Individualized continuous calorie restriction diet based on healthy Mediterranean diet recommendations aiming to achieve at least a 5% weight loss at the end of the intervention
Study NCT06395246 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eTRE
Description: early (morning) time-restricted eating pluss individualized continuous calorie restriction diet based on healthy Mediterranean diet recommendations aiming to achieve at least a 5% weight loss at the end of the intervention
Study NCT06213649 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Polyhexamethylene biguanide (PHMB)
Description: PHMB is a cationic antiseptic agent used for topical treatment of acanthamoeba keratitis (AK). Both treatment groups will take PHMB at least 4 times daily while on the allocated study drug.
Study NCT06213649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyhexamethylene biguanide (PHMB)
Description: PHMB is a cationic antiseptic agent used for topical treatment of acanthamoeba keratitis (AK). Both treatment groups will take PHMB at least 4 times daily while on the allocated study drug.
Study NCT06213649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical corticosteroid
Description: Dexamethasone sodium phosphate, 0.1% ophthalmic solution will be administered 4 times daily for 4 weeks, then 2 times daily for 2 weeks, then 1 time daily for 2 weeks.
Study NCT06213649 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Topical placebo
Description: An artificial tear ophthalmic solution will be administered 4 times daily for 4 weeks, then 2 times daily for 2 weeks, then 1 time daily for 2 weeks.
Study NCT06440343 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrates
Description: 60g of maltodextrin + fructose, 2:1 ratio
Study NCT06440343 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05387408 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Best Practice Health and Employment Opioid-related Policies
Description: The intervention will include information to promote policies and programs to prevent opioid abuse and aid recovery such as drug testing for opioids, health and employee assistance programs, job accommodations, and education to deliver training to prevent opioid use, and prevent stigma.
Study NCT05432557 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: external oblique intercostal plain block (EOIP)
Description: A high-frequency linear ultrasound probe will be placed in a longitudinal parasagittal orientation at the sixth intercostal space in the anterior midaxillary line. A 21G 10 cm needle will be inserted using an in plane approach. The tip of the needle will be placed into the fascial plane on the deep aspect of the external oblique muscle. A volume of 20 mL of LA mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine 2% and 5 mL of normal saline to make a mixture totaling 20 ml.) will be injected.
Study NCT05432557 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: subcostal transversus abdominis plane block (SCTAP)
Description: The US probe will be placed immediately below the costal margin on oblique plane toward the lateral close to midline to identify the rectus abdominis muscle. The transversus abdominis muscle will be identified lying posterior to the rectus muscle. An 8cm 22-gauge block needle will be inserted using an in- plane approach. transversus abdominis plane will be accessed by placing the needle adjacent to costal margin but medial to linea semilunaris. The needle will be advanced slowly in-plane to promote hydrodissection along the oblique subcostal line. A volume of 20 mL of LA mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine 2% and 5 mL of normal saline to make a mixture totaling 20 ml.) will be injected.
Study NCT04015557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Adult patients with homocystinuria due to cystathionine beta synthase (CBS) deficiency and controls will receive a single dose of Acetaminophen (1.5g) orally. Blood will be drawn at time 0, 2, 4, 6 and 8 hours after the acetaminophen dose to measure liver enzymes and markers of oxidative stress.
Study NCT04015557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: Patients with homocystinuria due to cystathionine beta synthase (CBS) deficiency and controls will receive again a normal dose of acetaminophen (1.5g) orally and one hour later oral N-acetylcysteine (70 mg per kilogram of body weight). Blood will be drawn at time 0, 2, 4, 6 and 8 hours after the acetaminophen dose to measure liver enzymes and markers of oxidative stress.
Study NCT06605703 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WW Clinic
Description: Telehealth platform that specializes in medical weight management and integrates the behavioral and lifestyle support from WW.
Study NCT06605703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion-Naltrexone
Description: Bupropion-Naltrexone
Study NCT04923971 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Purdue Pegboard
Description: Participants will assemble the pegboard with their left, right, and both hands in each environmental condition.
Study NCT05755789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loading bolus of cefoxitin
Description: Cefoxitin \[2g\] before incision
Study NCT05755789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loading bolus of cefoxitin
Description: Cefoxitin \[2g\] before incision
Study NCT05755789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent cefoxitin
Description: Additional bolus of cefoxitin \[1g\] every 2 hours until the end of surgical closure
Study NCT05755789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous infusion of placebo
Description: Continuous infusion of placebo from the end of the loading bolus until the end of surgical closure
Study NCT05755789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous infusion of cefoxitin
Description: Continuous infusion of cefoxitin \[0.5g/h\] from the end of the loading bolus until the end of surgical closure
Study NCT05755789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intermittent placebo
Description: Additional bolus of placebo every 2 hours until the end of surgical closure
Study NCT04850950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide fumarate 25mg Oral Tablet
Description: Tenofovir alafenamide fumarate initiated from the late pregnancy to the delivery date or postpartum month 1.
Study NCT06375850 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sesame oil
Description: A peripheral venous catheter will be channeled to the patient admitted to the unit and who requires it. The indications included in the guide for channeling venous access of the Marqués de Valdecilla hospital will be followed.~Once the venous access has been channeled, it will be fixed with, leaving the puncture point visible for future monitoring.~The sesame oil chosen for the project is Sesame bio - 100% pure vegetable oil from the Naissance brand.~To perform the procedure, two drops of sesame oil will be applied daily by the nurse in charge of the patient during the morning shift in the area about 2 cm above the insertion point and coinciding with the course of the vein channeled for intravenous therapy. A small massage of the area of application will be performed, with an approximate extension of 3x3cm, until its absorption. It will be left to dry in the air.
Study NCT06375850 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: After cannulation of the vein following the same procedure as explained in the intervention arm, patients belonging to the control arm will be administered two drops of saline solution.
Study NCT04881877 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synthetic nitrite Condom
Description: The condoms is composed of a synthetic nitrile rubber latex and 170 mm in length and is 53mm wide. It has a teat ended shape and bead retention mechanism at the top. It is pre-lubricated with silicone oil. It has a shelf-life of 5 years and clear and colourless. It is manufactured by Karex Industries. It is currently experimental.
Study NCT04881877 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Latex and graphene Condom
Description: The condom is composed of a natural rubber latex with graphene. It is 170 mm in length and is 53mm wide. It has a teat ended shape and bead retention mechanism at the top. It is pre-lubricated with silicone oil. It has a shelf-life of 5 years and is greyish in colour. It is manufactured by Karex Industries. It is currently experimental.
Study NCT04881877 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard latex condom
Description: The condoms is composed of a natural rubber latex. It is 180 mm in length and is 53mm wide. It has a teat ended shape and bead retention mechanism at the top. It is pre-lubricated with silicone oil. It has a shelf-life of 5 years and is natural in colour. It is manufactured by Karex Industries. It has World Health Organisation (WHO)/UNFPA, India Drug Control Authority, Conformitè Europëenne (CE) Mark of the European Union, South African Bureau of Standards and US FDA approval
Study NCT05087056 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MenABCWY vaccine
Description: Two doses of the MenABCWY vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, on a 0-, 24-month schedule in the ABCWY-24 Group, and a 0-, 48-month schedule in the ABCWY-48 Group.
Study NCT05087056 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose of Placebo (saline solution in pre-filled syringe), administered intramuscularly in the deltoid region of the non-dominant arm, at Day 1441 in the ABCWY-24 Group, and at Day 721 in the ABCWY-48 Group.
Study NCT04722978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine and carboplatin plus antibiotic (moxifloxacin)
Description: Standard chemotherapy (gemcitabine and carboplatin) plus antibiotic (moxifloxacin)
Study NCT04722978 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine combined with carboplatin plus placebo
Description: Standard chemotherapy (gemcitabine and carboplatin) plus placebo
Study NCT04757337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 6 x 3-week cycles corresponding to a maximal duration of 18 weeks
Study NCT04757337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Until progression up to 24 months
Study NCT06133543 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-assisted ICG-guided sentinel lymph node biopsy
Description: The robot-assisted ICG-guided sentinel node (SN) biopsy is conducted as follows: At the start of the operation, indocyanine green (ICG) solution is transscrotally injected into the testicular parenchyma. The patient is positioned in the nephrectomy posture. After port placement and docking of the robotic system, the sentinel node(s) should be visible with the fluorescence camera. The SN is removed and sent for immediate frozen section biopsy evaluation. The inguinal orchiectomy is performed subsequently until the biopsy results are available. If the biopsy is negative, the procedure concludes. If the biopsy shows viable tumor, indicating clinical stage IIA and the indication for systematic unilateral retroperitoneal lymph node dissection. The patient was informed about the potential expansion of the procedure upon study enrollment. After the procedure, all patients are placed under observation and do not receive adjuvant systemic treatment. The follow-up period extends to 2 years.
Study NCT05424809 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared decision-making model
Description: The model is based on a person-centred care process, where an exchange of information is carried out between the health professional and the patient to make the best decision that is consistent with the person's values and preferences.~A six-stage process constitutes the model: 1) Identificacion of the decision point, 2) design of a specific patient decision aid, 3) identification of possible barriers and ways to overcome them, 4) training for professionals, 5) 3-steps implementation of shared decision-making in clinical practice, 6) evaluation
Study NCT05733533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-2261 oral tablet
Description: HRS-2261 oral tablet, oral, BID
Study NCT05733533 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo to HRS-2261
Description: Matching placebo to HRS-2261, oral, BID
Study NCT05488353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin for Injection,Penpulimab Injection
Description: After completion of all screening activities, patients confirmed to be eligible will enter the study and receive the following treatments.~Neoadjuvant regimen (up to 4 cycles): Disitamab Vedotin for Injection, 2.0 mg/kg, given as an IV infusion on day 1, and Penpulimab Injection, 200 mg, on every 21 days On day 1 of the cycle, it is given as an intravenous infusion. Order of use: Disitamab Vedotin for Injection → Penpulimab Injection.
Study NCT05619523 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Developing Inclusive Youth (DIY)
Description: Developing Inclusive Youth (DIY) is a web-based curriculum tool that serves as the intervention program. The animated and narrated tool displays eight peer social exclusion scenarios in a range of familiar everyday social contexts (such as the playground and school). Children enter their responses while watching the scenarios. Responses include making decisions about inclusion and exclusion, evaluating the actions as okay or not okay, attributing feelings to includers, excluders, and excluded characters, and selecting reasons that best match their justification for their decisions and evaluations. The program includes teacher-guided group discussions following use of the tool in which teachers facilitate discussions about children's interpretations of the scenarios, evaluations, reflections regarding their own experiences of exclusion, and solutions. Participants will view and discuss 8 scenarios and engage in a discussion for each one over the course of 8 weeks.
Study NCT05193396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: hydrocortisone
Study NCT05193396 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablets
Study NCT05967910 — intervention group
Intervention type: OTHER
Intervention: chronic psychological stress
Description: Chronic psychological stress includes symptoms of anxiety and depression.
Study NCT02036723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Patients will receive bevacizumab at a dose 1.25 mg (in 0.05 ml of solution) as an intravitreal injection on day 1 and then every 28 days during 12 months.
Study NCT02036723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Patients will receive ranibizumab at a dose 0.50 mg (in 0.05 ml of solution) as an intravitreal injection on day 1 and then every 28 days during 12 months.
Study NCT05992038 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteotomy with putty
Description: Synthetic ceramic putty
Study NCT05992038 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional osteotomy
Description: conventional osteotomy
Study NCT05064800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran
Description: A single dose of Dabigatran on Day 1
Study NCT05064800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07321332/ritonavir + Dabigatran
Description: PF-07321332/ritonavir twice daily (BID) for Days 1 and 2 Single dose of Dabigatran on Day 2
Study NCT05064800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir + Dabigatran
Description: Ritonavir BID on Days 1 and 2 Single dose of Dabigatran on Day 2
Study NCT04913636 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment Gel
Description: In the evening subjects will perform their regular denture cleaning routine. They will be instructed to sleep without dentures. Subjects will rinse out their mouth with water (if subjects brush their oral mucosa with brush, they will be allowed to continue doing so) and apply the gel to their mucosa where they normally wear upper or lower denture.
Study NCT04913636 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Control
Description: Subjects will perform their regular denture cleaning routine.
Study NCT05141747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRG002
Description: Administrated intravenously
Study NCT05797090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crystalloid Cardioplegic solution
Description: To compare between conventional crystalloid cardioplegia with modified del Nido cardioplegia in mitral valve regurge replacement surgery.
Study NCT05098379 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-Rehabilitation Home Exercise Program
Description: Participants will engage in 150 minutes of exercise per week (30 min/day for 5 days/week) for 8 weeks and will have weekly virtual Exercise Coaching sessions with a trained project team member. Customized home exercise programs will be reviewed weekly during the coaching sessions and will be modified as needed to ensure participants can complete their exercises safely and effectively. Exercise coaches will send weekly messages to 'check-in' with participants in order to motivate and remind participants to adhere to their tailored home exercise programs.~During weekly exercise coaching sessions, exercises will be reviewed for form, safety, and progression. Exercises will be revised as needed to ensure that they are in line with participants' goals, needs, and preferences.
Study NCT06680830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NEU-411
Description: NEU-411, a potent, selective, orally bioavailable, highly permeable, brain penetrant, small molecule inhibitor of LRRK2 activity
Study NCT06680830 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally-administered matched placebo
Study NCT04703920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Talazoparib will be administered in increasing doses up to 1 mg orally once a day.
Study NCT04703920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: Belinostat will be administered in increasing doses up to 1000 mg/m2 IV once daily on days 1-5 of a 21-day cycle.
Study NCT06685588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU (fluorouracil)
Description: Topical 5-FU (fluorouracil) pretreatment prior to dovonex
Study NCT06685588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcipotriol
Description: Calcipotriol pre-treatment prior to PDT
Study NCT06682247 — intervention group
Intervention type: DRUG
Intervention: Chidamide, Tucidinostat; PD-1/PD-L1 inhibitor or double antibodies; Bevacizumab or tyrosine kinase inhibitors
Description: Chidamide, Tucidinostat; PD-1/PD-L1 inhibitor or double antibodies; Bevacizumab or tyrosine kinase inhibitors
Study NCT06685250 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic cholecystectomy
Description: Laparoscopic cholecystectomy
Study NCT06235957 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cast 3 weeks
Description: patients will be treated either in a cast or a brace, patients in group A are treated by cast immobilization for 3 weeks
Study NCT06235957 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Brace 1 week
Description: patients will be treated either in a cast or a brace, patients in group B are treated in a brace for 1 week
Study NCT05389839 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wechat program
Description: The experimental group used wechat program to calculate insulin dose to guide insulin treatment .
Study NCT05389839 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wechat program
Description: The experimental group used wechat program to calculate insulin dose to guide insulin treatment .
Study NCT04661319 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: video editing training
Description: 1. The subject's preoperative residency year, instrument experience, open surgery experience, laparoscopic surgery experience, and preoperative instrument proficiency are evaluated.~2. Basic anatomical and scientific education for laparoscopic cholecystectomy, practice laparoscopic instruments for at least 30 minutes every other week, and observe 3 cases of laparoscopic cholecystectomy.~3. Select a random experimental group.~4. For each selected group, 3 cases of surgical observation or 3 cases of video editing are performed.~5. Both groups operated on 10 cases, and both groups were discharged from the hospital after undergoing the same recovery procedure after the same operation.
Study NCT05432557 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: No LA injection
Study NCT05651087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LACUDY
Description: LACUDY:Insert 2mL twice a week for 4 weeks before going to bed